




Healthcare Industry News: HSMN NewsFeed
News Release - February 15, 2017
InGeneron Announces Changes in Management Team
HOUSTON--(Healthcare Sales & Marketing Network)--InGeneron, Inc., a regenerative medicine and cell therapy company, today announced changes in its leadership team. Michael Coleman, PhD, has stepped down as President and CEO and will join InGeneron’s Scientific Advisory Board. Ron Stubbers, MBA, formerly InGeneron’s Vice President of Operations, has been appointed President. The company has started the search process for candidates to replace Dr. Coleman as CEO. The company also announced the appointment of Glenn Winnier, PhD, as Chief Scientific Officer.“It is exciting to accept the position of President as we advance our clinical trial development plans in wound healing and orthopedic indications. My goal is to ensure effective operational support for establishing the therapeutic value of our approach and I believe 2017 will be transformative for the company,” added Mr. Stubbers.
Joining the company as new CSO, Dr. Winnier has over 18 years of experience in scientific leadership and a proven track record in the design of studies which have led to the successful commercialization of novel therapeutics. Glenn Winnier holds a PhD in cell biology from Vanderbilt University. He joins InGeneron from Memorial Hermann Healthcare System in Houston where he was Director of Clinical Research Operations at the Clinical Innovation and Research Institute.
About InGeneron
InGeneron is elevating the field of regenerative medicine by translating robust science into proven patient benefit. Our purpose is to set new therapeutic standards by enabling physicians to use the patients’ own regenerative cells at point of care. With the initial focus on key orthopedic and wound healing indications, we will make regenerative cell therapies broadly accessible across multiple medical fields. www.ingeneron.com
Source: InGeneron
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.